SNGX - Soligenix GAAP EPS of -$0.22 beats by $0.16 revenue of $0.2M in-line
2023-08-21 12:05:04 ET
More on Soligenix
- Soligenix gets FDA meeting to discuss phase 3 trial design of photodynamic therapy HyBryte
- Soligenix prices stock and warrants offering to raise $8.5M, shares down nearly 50%
- Soligenix surges ~250% after HyBryte shows compatibility with light device for blood cancer
- Soligenix stock sinks as FDA seeks additional positive results for cancer drug
- Seeking Alpha’s Quant Rating on Soligenix
- Earnings data for Soligenix
For further details see:
Soligenix GAAP EPS of -$0.22 beats by $0.16, revenue of $0.2M in-line